Article
Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer
Author(s):
In Partnership With:
Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.
Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.
Platinum-based chemotherapy has been a successful treatment for patients with urothelial cancer, but immunotherapies—particularly PD-1/PD-L1 antibodies—have captured much of the recent attention in the field, states Tagawa.
One-quarter of patients with urothelial cancer see durable responses with immunotherapy. Now, trials are focused on combination regimens, explains Tagawa.
